Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates
Biohaven (BHVN) shares were falling past 11% in recent Friday trading after the company reported a Q1 adjusted net loss that missed analysts' estimates. The biopharmaceutical company reported a Q1 adj
Biohaven On Thursday Reported Q1 2024 Adj. EPS $(1.77) Down From $(0.98) YoY
Biohaven On Thursday Reported Q1 2024 Adj. EPS $(1.77) Down From $(0.98) YoY
RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
Calendar of U.S. Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo
Biohaven | 10-Q: Quarterly report
Biohaven Reports Q1 Results
Biohaven 1Q Loss $179.5M >BHVN
Biohaven 1Q Loss $179.5M >BHVN
Around $1M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
Independent Director of Biohaven John Childs Buys 3.2% More Shares
Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN)
Biohaven(BHVN.US) Director Buys US$999.17K in Common Stock
$Biohaven(BHVN.US)$ Director Bailey Gregory purchased 25,503 shares of common stock on Apr 24, 2024 at an average price of $39.1785 for a total value of $999.17K.Source: Announcement What is statement
Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing
Gregory Bailey, Director, on April 24, 2024, executed a purchase for 25,503 shares in Biohaven (BHVN) for $999,169. Following the Form 4 filing with the SEC, Bailey has control over a total of 1,600,0
Biohaven Is Maintained at Buy by UBS
Biohaven Is Maintained at Buy by UBS
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO
Biohaven (BHVN) shares rose 6.3% in recent Tuesday trading after the company announced the closing of its underwritten public offering and disclosed Chief Executive Vlad Coric's purchase of company sh
UBS: Maintaining the Biohaven (BHVN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $59.00 to $60.00.
UBS: Maintaining the Biohaven (BHVN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $59.00 to $60.00.
UBS Maintains Buy on Biohaven, Raises Price Target to $60
UBS analyst Ashwani Verma maintains Biohaven with a Buy and raises the price target from $59 to $60.
Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing
Vlad Coric, Director, Chief Executive Officer, on April 22, 2024, executed a purchase for 121,951 shares in Biohaven (BHVN) for $4,999,991. Following the Form 4 filing with the SEC, Coric has control
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Becton Dickinson (BDX)
Biohaven Shares Are Trading Lower After the Company on Thursday Priced a 5.609 Million Share Offering at $41 per Share.
Biohaven Shares Are Trading Lower After the Company on Thursday Priced a 5.609 Million Share Offering at $41 per Share.
No Data